Considering the previously observed high incidence of TP53 Mut among MK AML patients [12], we assessed these signature mutations in our TP53 Mut MK AML cohort, as no studies, to the best of our knowledge, have been conducted to determine their incidence and prognostic utility among these patients. This evidence concerns the gene TP53 and acute myeloid leukemia.